Ratos’s Biolin Scientific sells Osstell

The purpose of the deal, which will not have any significant impact on Ratos's earnings, is to focus on Biolin's other business divisions.

Stockholm-based Biolin Scientific develops, manufactures and markets analytical instruments for research, development, quality control and clinical diagnostics. The company focuses on nanotechnology – primarily materials science, cell analysis and biophysics.

Its customers are mainly researchers at universities, research institutes and the industrial sector. With around 150 employees, Biolin's turnover reached SEK 233m and the company's EBITA totalled SEK 23m in 2013.

Ratos took Biolin private in November 2010. Ratos made an offer of SEK 11.50 per share, which gave the company a market cap of SEK 306m. With debt of around SEK 15m, the deal valued Biolin at roughly SEK 320m. In July 2011 Biolin Scientific acquired Danish medical equipment developer Sophion Bioscience.

Company
Based in Gothenburg, Osstell develops and sells instruments that measure the stability of dental implants. Its clients include dentists and oral surgeons worldwide. With 15 employees, the company had a turnover of SEK 36m in 2013.

People
Jan Wahlström is the CEO of Biolin. Jonas Ohlsson is the CEO of Osstell.

 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Healthcare
• Exits
• Sweden
• Ratos Holding
• Fouriertransform AB (FTAB)